AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07 2021 - 4:15PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on emerging immune control mechanisms applicable to
inflammation and immuno-oncology indications, today announced that
Hamza Suria, chief executive officer of AnaptysBio, will present at
the 39th Annual J.P. Morgan Healthcare Conference on Thursday,
January 14, 2021 at 9:10 a.m. ET. The conference will be conducted
virtually, and the audio presentation will be available via
https://jpmorgan.metameetings.net/events/healthcare21/sessions/35504-anaptysbio-inc/webcast?gpu_only=true&kiosk=true
A live webcast of the presentation will also be available
through the investor section of the AnaptysBio website at
https://ir.anaptysbio.com/events. A replay of the webcast will be
available for 30 days following the event.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on emerging immune control mechanisms applicable
to inflammation and immuno-oncology indications. The Company’s
proprietary anti-inflammatory pipeline includes its anti-IL-36R
antibody imsidolimab, previously referred to as ANB019, for the
treatment of rare inflammatory diseases, including generalized
pustular psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi
and ichthyosis; its anti-PD-1 agonist program, ANB030, for
treatment of certain autoimmune diseases where immune checkpoint
receptors are insufficiently activated; its BTLA modulator program,
ANB032, which is broadly applicable to human inflammatory diseases
associated with lymphoid and myeloid immune cell dysregulation; and
its anti-IL-33 antibody etokimab, previously referred to as ANB020,
for the treatment of chronic rhinosinusitis with nasal polyps, or
CRSwNP, and eosinophilic asthma. AnaptysBio’s antibody pipeline has
been developed using its proprietary somatic hypermutation, or SHM
platform, which uses in vitro SHM for antibody discovery and is
designed to replicate key features of the human immune system to
overcome the limitations of competing antibody discovery
technologies. AnaptysBio has also developed multiple therapeutic
antibodies in an immuno-oncology collaboration with
GlaxoSmithKline, including an anti-PD-1 antagonist antibody
(dostarlimab GSK4057190A), an anti-TIM-3 antagonist antibody
(cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody
(GSK4074386), and an inflammation collaboration with Bristol-Myers
Squibb, including an anti-PD-1 checkpoint agonist antibody
(CC-90006) currently in clinical development.
Contact:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024